Search Results 271-280 of 17549 for vitiligo

1. Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma - Mayo Clinic

   Note: Vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, and conditions ...

2. A Safety Study of SEA-TGT (SGN-TGT) in Patients With Advanced Cancer - Mayo Clinic

   colitis, pneumonitis, transaminitis); Participants with vitiligo, controlled type 1 diabetes mellitus, residual hypothyroidism requiring hormone replacement ...

3. Study of SC-003 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer - Mayo Clinic

   Active autoimmune disease, with exceptions of psoriasis not requiring systemic treatment, vitiligo, type 1 diabetes mellitus and hypothyroidism. History of ...

4. A Study To Assess The Safety, Tolerability, And Pharmacokinetics Of ABSK-011 In Patients With Advanced Solid Tumor - Mayo Clinic

   0) with the exception of which inclusion criteria allowed, alopecia, vitiligo and neurotoxicity Grade ≤2 that investigator believe don't affect safety ...

5. Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma - Mayo Clinic

   Active, known or suspected autoimmune disease other than patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not ...

6. Lichen planus - Doctors and departments - Mayo Clinic

   ... Vitiligo, Oral lichen planus, Nonmelanoma skin cancer, Tuberous sclerosis, Klippel-Trenaunay syndrome, Melasma, Alopecia areata, Diffuse capillary ...

7. Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma - Mayo Clinic

   Active, known or suspected autoimmune disease; note: subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual ...

8. TheraSphere With and Without Durvalumab and Tremelimumab for HCC - Mayo Clinic

   Patients with vitiligo or alopecia 2. Patients with hypothyroidism (e.g. following Hashimoto's syndrome) stable on hormone replacement therapy 3. Any ...

9. Testing The Role Of DNA Released From Tumor Cells Into The Blood In Guiding The Use Of Immunotherapy After Surgical Removal Of The Bladder, Kidney, Ureter, And Urethra For Urothelial Cancer Treatment, MODERN Study - Mayo Clinic

   PRE-REGISTRATION: Patients with vitiligo, endocrine deficiencies including type I diabetes mellitus, thyroiditis managed with replacement hormones including ...

10. A Study of a Personalized Neoantigen Cancer Vaccine - Mayo Clinic

    ... vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted.